August 12, 2019

2020 ASH Review Faculty

Binay Shah, MD, MHA – Binaytara Foundation

Dr. Binay Shah is a board certified oncologist and hematologist at PeaceHealth United General Hospital, Sedro Woolley, WA. Dr. Shah’s area of interest is in health outcomes and health disparities among cancer patients, and he has published and presented over 125 papers in various journals and meetings.

He is invited nationally and internationally to speak on various cancers and global health. He has the distinction of developing the nation’s first statewide personalized cancer care tumor board as  president of the Idaho Society of Clinical Oncology. Dr. Shah is a patient advocate, and humanitarian. He founded the Binaytara Foundation to promote health and education in underprivileged communities.

Roland Walter, MD, PhD, MS – Fred Hutchinson Cancer Research Center

Dr. Roland Walter is a hematologist who specializes in treating acute myeloid leukemia, or AML. His research seeks to develop new and improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate the AML stem cells, and then to bring these therapies to patients.

Parameswaran Venugopal, MD – Rush University Medical Center

Dr. Venugopal, MD is a practicing Hematologist & Oncologist in Chicago, IL. He completed a residency at Rush University Medical Center. Dr. Venugopal also specializes in Hematology and Internal Medicine. He currently practices at Consultants In Hematology and is affiliated with Rush Oak Park Hospital and Rush University Medical Center. Dr. Venugopal accepts multiple insurance plans including Aetna, Humana, and Medicare. Dr. Venugopal also practices at Div. of Hematology Oncology and Section of Medical Oncology in Chicago, IL

George Rodgers, MD, PhD – University of Utah Health Sciences Center

George M. Rodgers, MD, PhD is Professor of Medicine and Pathology at the University of Utah Health Sciences Center.  His is also Medical Director of the Coagulation Laboratory at ARUP Laboratories. He received his M.D. and Ph.D. degrees from Tulane University, did internal medicine training at Baylor College of Medicine, and received hematology fellowship training at UCSF.Dr. Rodgers’ clinical research interests include benign hematology, especially disorders of hemostasis and thrombosis.  He has published over 200 journal articles and book chapters as well as 4 books, primarily on coagulation subjects. He is an associate editor of Wintrobe’s Clinical Hematology textbook.

Krish Patel, MD –

Krish Patel is a clinical investigator and Director of the Lymphoma Program at the Swedish Cancer Institute (SCI) in Seattle, Washington.  Dr. Patel completed his medical school, residency, and fellowship training at Duke University School of Medicine where he served as a Chief Resident in Internal Medicine.  In 2016, he joined the Swedish Cancer Institute Center for Blood Disorders and Stem Cell Transplantation as a clinical investigator. Clinically, he is focused on all aspects of lymphoma and CLL related care.  He has a particular research interest in the development of novel targeted agents, immunotherapies, and cellular therapies to advance care for patients with lymphoid malignancies. He is currently a principal investigator for numerous phase I-III therapeutic lymphoma and CLL clinical trials at SCI.

Mazyar Shadman, MD, MPH –

Mazyar Shadman, MD, MPH, is an assistant member at Fred Hutchinson Cancer Research Center and an assistant professor of medicine at University of Washington (UW). He is a hematologic malignancies expert who specializes in treating patients with lymphoma/ chronic lymphocytic leukemia (CLL). He is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR-T cell) and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL.  He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies. Dr. Shadman received his M.D. from Tehran University in Iran. He finished internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He returned to Seattle and finished his training in hematology and medical oncology fellowships at the UW and Fred Hutchinson cancer research center. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for National Cancer Institute’s cancer research training program at Fred Hutch, where he studies cancer epidemiology.